诺华的cMET新药INC280

一起坚强 · 发表于 2013-10-25 09:22:24

三天不学习赶不上刘少奇

努力学习

zx5211 · 发表于 2013-10-26 22:16:09

为什么都是肺癌的药，是放弃肝癌了吗？

奔四的顽石 · 发表于 2013-10-27 19:58:49

zx5211 发表于 2013-10-26 22:16

登录/注册后可看大图

为什么都是肺癌的药，是放弃肝癌了吗？

因为肺癌太多了，药厂考虑经济效益，当然优先研发肺癌的药啊。

costa_na · 发表于 2013-11-6 00:17:33

老马我看AACR这篇论文里面写的280对cMet的IC50貌似只有0.13nM 是实验环境或者计量单位不同造成的吗？
INCB28060 inhibits c-MET kinase activity with an average IC50 value of 0.13 nM (Table 1).

1078-0432.CCR-11-1157.full.pdf (836.4 KB, 下载次数: 217)

1548588601 · 发表于 2013-11-7 09:32:47

算是好消息，看到实验组在广州，北京有吗其他地方有吗

paladin0704 · 发表于 2013-11-16 15:09:53

有这个药的新消息吗

淡淡若雨 · 发表于 2013-11-16 21:14:10

非常期待好消息

淡淡若雨 · 发表于 2013-11-16 21:17:55

一只白杨发表于 2013-9-26 23:45

登录/注册后可看大图

最近我经手的一例病人，服用易瑞沙+INC280，肺部病灶几乎完全缓解。国庆后准备在400mg 剂量组再增加一些病例 ...

请问还有更多的前缘信息吗？期待你的消息，希望你能详细给群里广大的病友说说感激不尽

625568367 · 发表于 2013-11-16 21:32:14

感谢大家的信息继续期待

playrain · 发表于 2013-11-16 21:59:46

本帖最后由 playrain 于 2013-11-16 22:00 编辑

c-Met抑制剂比较

选择性抑制
溶解性

抑制剂名称	c-Met	其他
Crizotinib (PF-02341066)	+	ALK
Tivantinib (ARQ 197)	+
AMG-458	+
Golvatinib (E7050)	++	VEGFR2/KDR
NVP-BVU972	++
BMS-794833	+++	VEGFR2/KDR
JNJ-38877605	+++
Cabozantinib (XL184, BMS-907351)	+++	FLT4/VEGFR3,VEGFR2/KDR,Axl,FLT1/VEGFR1,FLT3,c-RET,Tie-2,c-Kit
AMG-208	+++
PHA-665752	+++
BMS-777607	+++	Axl
SGX-523	+++
MK-2461	+++	PDGFR-β,FGFR-1,FGFR-2,FGFR-3
PF-04217903	+++
SU11274	+++
Foretinib (GSK1363089)	++++
INCB28060	++++
MGCD-265	++++	VEGFR2/KDR,VEGFR1/FLT1,VEGFR3/FLT4,Tie-2

Notes:1. For more details, such as half maximal inhibitory concentrations (IC50s) and related working concentrations of any inhibitor, please click on the link of the inhibitor of interest.
2. IC50 refers to how much of an inhibitor is needed to inhibit the activities of any kinase by 50%.
3. "+" refers to an inhibitor that has a significant effect on the specific signaling target. If the IC50 of the minor target of any inhibitor is more than 1000 times greater than the IC50 of the major target, its minor target will not be mentioned in any table.
4. There may be oversights of the effects of inhibitors on signaling targets. Please inform us if you notice any.